ARCHIVES

Control-Arm CML Patients In Phase III Gleevec Study Allowed To Switch.

This article is from The Cancer Letter archive.

Vol. 28 No. 04 | January 25, 2002

Download PDF Visit The Full Archive

Related Articles

Ethics Commission Say HHS Should Test Injury Compensation

June 18, 1982

Excerpts From Potti’s Application to Practice Medicine In South Carolina

December 9, 2011

PR Firm Hired By American Cancer Society Also Represents “Team KOOL Green”.

January 28, 2000

ODAC Reviews Post-Marketing Studies for Eight Indications

February 21, 2003

Bypass Budget For FY 1992 Shown In Chart

May 18, 1990

Two Children Achieve Remission With CD19 Immunotherapy

March 29, 2013